Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three ...

Pacira BioSciences: Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences ...

Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

About Pacira Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three ...